Search for a trial

A PHASE Ia/Ib DOSE-ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION

This study has been transitioned to CTIS with ID 2023-506311-18-00 check the CTIS register for the current data. This Phase Ia/Ib study will evaluate the safety, pharmacokinetics, immunogenicity (as applicable for study biotherapeutics), preliminary…

A Prospective Investigation to Assess the Diagnostic Yield of using a Robotic Navigational Bronchoscopy System with Adjunct Real-time Imaging

The primary objective of this Clinical Investigation is to evaluate the diagnostic yield using the Ion Endoluminal System when used with adjunctive 3D imaging modalities for the biopsy of peripheral pulmonary nodules (PPNs). In a first phase, the…

ELDAPT: Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the oPtimal Treatment strategy

Developing a clinically applicable geriatric screening instrument to stratify medically fit patients who may benefit from intensified treatment strategies and frail patients who will undergo best supportive care (which may include palliative RT), (2…

A clinical performance study for testing FFPE tissue samples, with therascreen® KRAS RGQ PCR kit, to determine KRAS G12C mutation for potential enrollment into clinical study BO45217

The objective of the diagnostic performance study is to determine the KRAS G12C status in tissues of NSCLC tumors collected from potential study subjects, in order to determine their biomarker eligibility for study BO45217. Currently, there is no…

Assessment of the Safety and Performance of the AB1 Electrosurgical System for Bronchoscopic Microwave Ablation of Lung Tissue (AB1MALT)

The overall purpose of this study is to confirm the clinical safety and performance of the AB1 instrument in subjects undergoing bronchoscopic pulmonary nodule microwave ablation procedures performed using the AB1 electrosurgical system.

Assessment of the Safety and Performance of the AB1 Electrosurgical System for Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates (AB1MALTISC)

The overall purpose of this study is to characterise the clinical safety and performance of the AB1 instrument in patients with pathologically confirmed malignancy eligible for surgical resection of their nodule, receiving bronchoscopic ablation…

Safety and efficacy of a flexible endobronchial sampling instrument that obtains a CORe sample from KeY suspected areas of pulmonary and mediastinal lesions.

The primary objective of this clinical feasibility study is to assess the overall diagnostic yield of the Investigational Device in comparison to standard care. The secondary objective is to assess the safety issues that possibly occur while using…

Feasibility trial on combination of platinum doublets and hypofractionated radiotherapy for locally advanced stage non-small cell lung carcinoma

To assess the safety of cisplatin doublets with hypofractionated radiotherapy (24 x2.75Gy).

Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics , Pharmacodynamics, and Efficacy of CLN-081 in Patients with Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy

Phase 1Primary ObjectivesTo assess the safety and tolerability of orally administered CLN-081 monotherapy.To define the maximum tolerated dose (MTD) of orally administered CLN-081 monotherapy.Secondary ObjectivesTo assess the anti-tumor activity.To…

Non-Ionizing Metabolic Imaging using robust phosphorus MRI to predict treatment efficacy.

Primary objectives pancreatic cancer:• In this clinical pilot study, we will assess the effect size to perform a power calculation for a subsequent clinical trial. Therefore we want to evaluate the ability of metabolic 7T MRI imaging to determine…

A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with
BRAFV600-mutant Non-small Cell Lung Cancer

Primary Objective:To evaluate the efficacy of encorafenib + binimetinib in treatment-naïve and previously treated patients with BRAFV600E-mutant NSCLC as measured by ORR.Secondary objectives:1. To evaluate the efficacy of encorafenib + binimetinib…

A Phase 3, randomized, open label study of lorlatinib (PF 06463922) monotherapy versus crizotinib monotherapy in the first line treatment of patients with advanced ALK positive non small cell lung cancer

This study has been transitioned to CTIS with ID 2023-509169-19-00 check the CTIS register for the current data. To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival…

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)

This study has been transitioned to CTIS with ID 2023-506541-39-00 check the CTIS register for the current data. Monotherapy (Parts A, B*, D, E, F and G)Primary Objectives - Evaluate the safety and tolerability of Tarlatamab - Part A only: Determine…

A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced nonsmall cell lung cancer (NSCLC) (CINC280A2201)

Primary: To evaluate the antitumor activity of INC280, as measured by overall response rate (ORR) as by a blinded independent review committee, by cohort.Secondary: Duration of response (DOR), ORR and DOR by investigator, time to response (TTR),…

proSpecTive sAmpling in dRiver muTation pulmonary oncology patients on Tyrosine Kinase Inhibitors

To collect repeated samples of blood from patients (starting) on TKI, for liquid mutation testing to assess the clinical relevant cutoff value, and pharmacokinetic analysis.

A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma (CNIR178X2201)

Primary: • Part 1:To evaluate the efficacy of NIR178 and PDR001 combination in patients with selected advanced solid tumors and diffuse large B cell lymphoma (DLBCL). • Part 2: To assess the efficacy of several intermittent dosing schedules of…

A Phase II, Randomized, Open-label Platform Trial Utilizing a MastercProtocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants (study 205801)

Primary:To determine whether experimental regimens provide evidence for improved survival (randomization to death) over standard of care (SoC) therapy in NSCLC patients.Secondary:Milestone survival, measures of antitumor activity, safety and…

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC),
Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Objectives:To evaluate the following in NSCLC patients with EGFR or HER2 exon 20 insertion mutations (includingduplication mutations) who are treated with poziotinib:Primary Objective:Objective Response Rate (ORR)Secondary Objectives:• Disease…

The beneficial value of 18F FDG PET/CT in the follow-up of stage III non-small cell lung cancer patients

Primary Objective The primary objective of this study is to compare the 3-year overall survival of stage III NSCLC patients during follow-up surveillance with 18F FDG PET/CT versus follow-up with conventional CT surveillance. Secondary Objectives…

PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in small-cell Lung cancer patients

The primary objective is to show that brain MRI surveillance alone is non-inferior in terms of overall survival (OS) to brain MRI surveillance combined with prophylactic cranial irradiation (PCI) for the treatment of small cell lung cancer (SCLC).